The efficacy, tolerance and adverse events during treatment with VMP in plasma cell myeloma patients
Abstract
In this paper we describe two patients with plasma cell myeloma (PCM) treated with bortezomib-containing regimen VMP (bortezomib, melphalan, prednisone); the first case was 76-years-old woman who was qualified to VMP treatment. She obtained 3 cycles of chemotherapy, which were complicated by infections, deep venous thrombosis right lower limb, seizure and pancytopenia. Following she was qualified to radiation therapy because of changes in the parietal bone of skull (20 Gy/g). Due to patient’s age, many adverse events associated with VMP treatment and defections from therapeutic program with bortezomib patient was qualified to the treatment with cyclophosphamide and prednisone. The second case of 68-year-old patient with PCM and concomitant renal failure was treated with VMP. He achieved very good partial response after 5 cycles of chemotherapy. This report reveals therapeutic efficacy, tolerance and adverse events associated with VMP treatment in elderly patients and accompanying renal failure with plasma cell myeloma.
Keywords: plasma cell myelomabortezomibadverse eventsrenal failure
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)